Special issue: Nephrogenic systemic fibrosis

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 6, 2009, Pages 1233-1235

  Leiner, Tim ^a   Kucharczyk, Walter ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM CHELATE; HEAVY METAL; LANTHANIDE;

BIOAVAILABILITY; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; DIALYSIS; EDITORIAL; ESOPHAGUS; GLOMERULUS FILTRATION RATE; HEART; INCIDENCE; JOINT CONTRACTURE; KIDNEY; LUNG; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; RADIATION HAZARD; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; SCIENTIFIC LITERATURE; SKELETAL MUSCLE; SKIN; SKIN DISEASE; URINARY EXCRETION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 73649126572     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21985     Document Type: Editorial

References (27)

1. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108. Erratum in: Nephrol Dial Transplant 2006;21:1745.
2. Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009. DOI: 10.1093/ndt/gfp4g4.
3. United States Food and Drug Administration. FDA requests boxed warning for contrast agents used to improve MRI images. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2007/ucm108919.htm Accessed September 21, 2009.
4. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-816.
5. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009;250:371-377.
6. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168-175.
7. Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-975.
8. Heinz-Peer G, Neruda A, Watschinger B, et al. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2009 [Epub ahead of print] doi: 10.1016/j.ejrad.2009.06.028.
9. Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656-664.
10. Weinreb JC, Abu-Alfa A. Gadolinium based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? J Magn Reson Imaging 2009;30:1236-1239.
11. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging 2009;30:1240-1248.
12. Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249-1258.
13. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009;30:1259-1267.
14. Sieber MA, Steger-Hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging 2009;30:1268-1276.
15. Newton BB, Jimenez SA. The mechanism of NSF: new evidence challenging the prevailing theory. J Magn Reson Imaging 2009;30:1277-1283.
16. Vakil V, Sung JJ, Piecychna M, et al. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. J Magn Reson Imaging 2009;30:1284-1288.
17. Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-1297.
18. Kooman JP. Estimation of renal function in patients with chronic kidney disease. J Magn Reson Imaging 2009;30:1341-1346.
19. Silberzweig J, Chung M. Removal of gadolinium by dialysis: review of different strategies and techniques. J Magn Reson Imaging 2009;30:1347-1349.
20. Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada and Europe. J Magn Reson Imaging 2009;30:1357-1363.
21. Miki Y, Isoda H, Togashi K. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital. J Magn Reson Imaging 2009;30:1364-1365.
22. Prince MR, Zhang H, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging 2009;30:1298-1308.
23. Roditi GH, Maki JH, Oliveira G, Michaely HJ. Renovascular imaging in the NSF era. J Magn Reson Imaging 2009;30:1323-1334.
24. Mazhar SM, Shiehmorteza M, Kohl C, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-1322.
25. Martin DR, Semelka RC, Chapman A, et al. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009;30:1350-1356.
26. Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-1312.
27. Abujudeh HH, Rolls H, Kaewlai R, et al. Retrospective assessment of the prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009;30:1335-1340.